HIT in People With Type 1 Diabetes

High-Intensity Interval Training Improves Aerobic Capacity and Abolishes the Decline in Blood Glucose Observed During Moderate-Intensity Continuous Training Sessions in People With Type 1 Diabetes

Few people with type 1 diabetes achieve exercise guidelines and many programmes designed to increase physical activity have failed. High-intensity interval training (HIT) has been shown to be a time-efficient alternative to traditional moderate-intensity continuous training (MICT) in various groups without type 1 diabetes. A single bout of HIT does not increase the risk of hypoglycaemia in people with type 1 diabetes. This study aimed to assess whether HIT a safe, effective and time-efficient training strategy to improve cardio-metabolic health and reduce the risk of hypoglycaemia in people with type 1 diabetes.

Study Overview

• Status: Completed
• Conditions: Type1diabetes
• Intervention / Treatment: Other: HIT; Other: MICT

Detailed Description

This study aimed to investigate whether 1) six weeks of high-intensity interval training (HIT) induces similar improvements in cardio-metabolic health markers as moderate-intensity continuous training (MICT) in people with type 1 diabetes, and 2) whether HIT abolishes acute reductions in plasma glucose observed following MICT sessions. Fourteen sedentary individuals with type 1 diabetes (n=7 per group) completed six weeks of HIT or MICT 3 times per week. Pre- and post-training measurements were made of 24h interstitial glucose profiles (using continuous glucose monitors (CGMS)) and cardio-metabolic health markers (V ̇O2peak, blood lipid profile and aortic pulse wave velocity; aPWV). Capillary blood glucose concentrations were assessed before and after exercise sessions throughout the training programme to investigate changes in blood glucose during exercise in the fed state.

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Merseyside
    • Liverpool, Merseyside, United Kingdom, L3 3AF
      • Liverpool John Moores University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• duration of type 1 diabetes >6 months
• basal bolus regimen
• no significant history of hyper- or hypoglycaemia (determined from medical history)

Exclusion Criteria:

duration of type 1 diabetes <6 months,

• insulin pump therapy
• significant history of hyper- or hypoglycaemia (determined from medical history)
• obesity (BMI >30 kg∙m-2)
• pregnancy or planning pregnancy
• uncontrolled hypertension (>180/100 mmHg)
• angina, autonomic neuropathy
• taking any medication that affects heart rate
• major surgery planned within 6 weeks of the study
• severe nonproliferative
• unstable proliferative retinopathy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HIT training; 6 weeks of high-intensity interval training (HIT)	Other: HIT; Participants completed 6 weeks of HIT
Experimental: Moderate intensity training; 6 weeks of moderate-intensity continuous training (MICT)	Other: MICT; Participants completed 6 weeks of MICT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximal aerobic capacity	Maximal aerobic capacity test pre and post 6-week training intervention	change in baseline maximal aerobic capacity at 6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vascular stiffness	Aortic pulse wave velocity to measure vascular stiffness	change in baseline vascular stiffness at 6 weeks

Collaborators and Investigators

• Sponsor: Liverpool John Moores University

Study record dates

Study Major Dates

• Study Start (Actual): March 9, 2015
• Primary Completion (Actual): October 10, 2017
• Study Completion (Actual): October 10, 2017

Study Registration Dates

• First Submitted: May 9, 2018
• First Submitted That Met QC Criteria: June 1, 2018
• First Posted (Actual): June 4, 2018

Study Record Updates

• Last Update Posted (Actual): June 4, 2018
• Last Update Submitted That Met QC Criteria: June 1, 2018
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: T1D_PARTB

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plans to make data available to others

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No